Brill Establishes Subsidiary in the United States
Brill, the global pharmaceutical company specializing in ophthalmology, announced the establishment of a subsidiary in the United States with headquarters in Miami, Florida, a manufacturing center in Boston, Massachusetts, and strategic locations for distributing healthcare solutions throughout the country.
Additionally, Shawn Mullen has been appointed Commercial Director of Brill’s US Eye Health, effective April 1, 2024. Mr. Mullen’s operational and commercial leadership abilities are paired with extensive experience in the ophthalmic environment for over 25 years, noted the company.
The company advised that it will initiate operations in the United States by sponsoring several key ophthalmology congresses, including those of the American Academy of Ophthalmology, the American Academy of Optometrist, American Society of Cataract and Refractive Surgery, and the Tear Film and Ocular Surface Society, among others.
As part of the strategy to enter and establish the corporation in the United States and specifically in the ophthalmology pharmaceutical market, Brill plans to launch several products to improve the ophthalmology clinical practice and the lives of patients.
The company’s noncontact, portable Corneal Esthesiometer Brill will be launched in May 2024. This FDA-approved medical device is intended to enhance the efficiency of the “Complete Ophthalmology Examination” in physician’s practice.
According to the company, the Corneal Esthesiometer Brill measures corneal sensitivity in a precise, reproducible way. By analyzing corneal sensitivity, ophthalmology doctors will be able to diagnose, monitor, and follow-up therapies in multiple pathologies in which the corneal nerves are affected.
With European and FDA registrations, the noninvasive esthesiometer is available on the worldwide market for the evaluation of corneal-nerve status as a useful biomarker in the diagnosis and prognosis of eye health in highly prevalent diseases, such as glaucoma, herpes, and dry eye among others.
Furthermore, the device will allow ophthalmologists to differentiate stages of diseases such as neurotrophic keratitis, diabetic keratitis, and dry eye, and to monitor patients who have undergone refractive surgery or corneal transplants and those who wear contact lenses.
Brill has conducted clinical studies at Bascom Palmer Eye Institute in Miami, Florida; Duke University in Durham, North Carolina; Harvard Medical School in Boston, Massachusetts; Tufts Medical Center in Boston, Massachusetts; Baylor College of Medicine in Houston, Texas; and other prestigious institutions.
“The Corneal Esthesiometer Brill will allow ophthalmologists and optometrists to detect early stages of corneal sensation loss, allowing us to prescribe more specific treatments and monitor their effectiveness through a noninvasive and cost-effective diagnostic tool,” commented ophthalmologist Alfonso Sabater, MD, of Bascom Palmer Eye Institute in the company’s press release.